A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin

Clinical Cardiology

Volumn 26, Issue 3, 2003, Pages 112-118

  Hunninghake, Donald B ^a   McGovern, Mark E ^b   Koren, Michael ^c   Brazg, Ronald ^d   Murdock, David ^e   Weiss, Stuart ^f   Pearson, Thomas ^g  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Kos Pharmaceuticals Inc   (United States)

^c Jacksonville Center for Clinical Research   (United States)

^d Rainier Clin Research Clinic   (United States)

^e Cardiovasc Assoc N WI Care F I   (United States)

^f San Diego Composites Inc   (United States)

^g UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Cholesterol; Coronary disease; Hypercholesterolemia; Lipoproteins

Indexed keywords

AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOPATHY; RANDOMIZED CONTROLLED TRIAL;

EID: 0037343026     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960260304     Document Type: Article

References (21)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholestorelemia. N Engl J Med 1995;333:1301-1307
2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS (for the Air Force/Texas Coronary Atherosclerosis Prevention Study). J Am Med Assoc 1998;279:1615-1622
3. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
4. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357
6. Foot DK, Lewis RP, Pearson TA, Beller GA: Demographics and cardiology, 1950-2050. J Am Coll Cardiol 2000;35:1067-1081
7. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-714
8. Rubins HB, Robins SJ, Collins D, Iranmanesh A, Wilt TJ, Mann D, Mayo-Smith M, Faas FH, Elam MB, Rutan GH, Anderson JW, Kashyab ML, Schectman G, for the Department of Veterans Affairs HDL Intervention Trial Study Group: Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol 1995;75:1196-1201
9. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-418
10. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB, for the VA-HIT study group: Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: A randomized controlled trial. J Am Med Assoc 2001;285:1585-1591
11. Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-1085
12. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipopretein B. N Engl J Med 1990;323:1289-1298
13. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. J Am Med Assoc 1975;231:360-381
14. Brown BG, Zhao X-Q, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-1592
15. Knopp RH, Alagona P, Davidson M, Goldberg AC, Kafonek SD, Kashyap M, Sprecher D, Superko HR, Jenkins S, Marcovina S: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47:1097-1104
16. Morgan JM, Capuzzi DM, Guyton JR, Centor RM, Goldberg R, Robbins DC, DiPette D, Jenkins S, Marcovina S: Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: A placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996;1:195-202
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc 1993;269:3015-3023
18. Goldberg A, Alagona P Jr, Capuzzi DM, Guyton J, Morgan JM, Rodgers J, Sachson R, Samuel P: Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100-1105
19. Norman DJ, Illingworth DR, Munson J, Hosenpud J: Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin (letter). N Engl J Med 1988;318:46-47
20. Reaven P, Witztum JL: Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988;109:597-598
21. Guyton JR, Capuzzi DM: Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol 1998;82:82U-84U